O	0	4	CD56	CD56	NN	B-NP
O	4	5	+	+	CC	I-NP
O	6	14	putative	putative	JJ	I-NP
B-Cancer	15	22	natural	natural	JJ	I-NP
I-Cancer	23	29	killer	killer	NN	I-NP
I-Cancer	30	34	cell	cell	NN	I-NP
I-Cancer	35	44	lymphomas	lymphoma	NNS	I-NP
O	44	45	:	:	:	O
O	46	56	production	production	NN	B-NP
O	57	59	of	of	IN	B-PP
O	60	69	cytolytic	cytolytic	JJ	B-NP
O	70	79	effectors	effector	NNS	I-NP
O	80	83	and	and	CC	O
O	84	91	related	related	JJ	B-NP
O	92	100	proteins	protein	NNS	I-NP
O	101	110	mediating	mediate	VBG	B-VP
B-Cell	111	116	tumor	tumor	NN	B-NP
I-Cell	117	121	cell	cell	NN	I-NP
O	122	131	apoptosis	apoptosis	NN	I-NP
O	131	132	?	?	.	O

O	134	143	Apoptosis	Apoptosis	NN	B-NP
O	144	146	is	be	VBZ	B-VP
O	147	148	a	a	DT	B-NP
O	149	158	regulated	regulated	JJ	I-NP
O	159	163	form	form	NN	I-NP
O	164	166	of	of	IN	B-PP
B-Cell	167	171	cell	cell	NN	B-NP
O	172	177	death	death	NN	I-NP
O	178	182	that	that	WDT	B-NP
O	183	186	may	may	MD	B-VP
O	187	189	be	be	VB	I-VP
O	190	199	triggered	trigger	VBN	I-VP
O	200	202	by	by	IN	B-PP
B-Cell	203	210	natural	natural	JJ	B-NP
I-Cell	211	217	killer	killer	NN	I-NP
O	218	219	(	(	(	O
B-Cell	219	221	NK	NK	NN	B-NP
O	221	222	)	)	)	O
O	223	225	or	or	CC	O
B-Cell	226	235	cytotoxic	cytotoxic	JJ	B-NP
I-Cell	236	237	T	T	NN	I-NP
I-Cell	238	243	cells	cell	NNS	I-NP
O	243	244	,	,	,	O
O	245	250	which	which	WDT	B-NP
O	251	257	effect	effect	VBP	B-VP
O	258	264	target	target	NN	B-NP
B-Cell	265	269	cell	cell	NN	I-NP
O	270	275	lysis	lysis	NN	I-NP
O	276	278	by	by	IN	B-PP
O	279	288	cytolytic	cytolytic	JJ	B-NP
O	289	297	effector	effector	NN	I-NP
O	298	301	and	and	CC	O
O	302	309	related	related	JJ	B-NP
O	310	318	proteins	protein	NNS	I-NP
O	319	326	through	through	IN	B-PP
O	327	334	complex	complex	JJ	B-NP
B-Immaterial_anatomical_entity	335	348	intracellular	intracellular	JJ	I-NP
O	349	356	signals	signal	NNS	I-NP
O	356	357	.	.	.	O

O	358	362	This	This	DT	B-NP
O	363	368	study	study	NN	I-NP
O	369	372	was	be	VBD	B-VP
O	373	378	aimed	aim	VBN	I-VP
O	379	381	to	to	TO	I-VP
O	382	393	investigate	investigate	VB	I-VP
O	394	401	whether	whether	IN	B-SBAR
O	402	407	there	there	EX	B-NP
O	408	410	is	be	VBZ	B-VP
O	411	420	selective	selective	JJ	B-NP
O	421	431	expression	expression	NN	I-NP
O	432	434	of	of	IN	B-PP
O	435	440	these	these	DT	B-NP
O	441	450	cytolytic	cytolytic	JJ	I-NP
O	451	458	markers	marker	NNS	I-NP
O	459	461	in	in	IN	B-PP
O	462	465	the	the	DT	B-NP
O	466	474	putative	putative	JJ	I-NP
B-Cancer	475	477	NK	NK	NN	I-NP
I-Cancer	477	478	-	-	HYPH	B-NP
I-Cancer	478	482	cell	cell	NN	I-NP
I-Cancer	483	492	lymphomas	lymphoma	NNS	I-NP
O	493	496	and	and	CC	B-PP
O	497	504	whether	whether	IN	B-SBAR
O	505	510	there	there	EX	B-NP
O	511	513	is	be	VBZ	B-VP
O	514	525	correlation	correlation	NN	B-NP
O	526	530	with	with	IN	B-PP
O	531	536	zonal	zonal	JJ	B-NP
B-Cell	537	542	tumor	tumor	NN	I-NP
I-Cell	543	547	cell	cell	NN	I-NP
O	548	553	death	death	NN	I-NP
O	554	556	in	in	IN	B-PP
O	557	562	these	these	DT	B-NP
B-Cancer	563	569	tumors	tumor	NNS	I-NP
O	569	570	.	.	.	O

O	571	581	Expression	Expression	NN	B-NP
O	582	584	of	of	IN	B-PP
O	585	588	the	the	DT	B-NP
O	589	598	cytolytic	cytolytic	JJ	I-NP
O	599	608	effectors	effector	NNS	I-NP
O	609	617	perforin	perforin	NN	I-NP
O	617	618	,	,	,	O
O	619	627	granzyme	granzyme	NN	B-NP
O	628	630	B9	B9	NN	I-NP
O	630	631	,	,	,	O
O	632	635	and	and	CC	O
O	636	639	the	the	DT	B-NP
B-Cellular_component	640	647	granule	granule	NN	I-NP
I-Cellular_component	648	656	membrane	membrane	NN	I-NP
O	657	664	protein	protein	NN	I-NP
O	665	669	TIA1	TIA1	NN	I-NP
O	670	674	were	be	VBD	B-VP
O	675	683	examined	examine	VBN	I-VP
O	684	686	in	in	IN	B-PP
O	687	689	24	24	CD	B-NP
O	690	698	putative	putative	JJ	I-NP
B-Cancer	699	701	NK	NK	NN	I-NP
I-Cancer	701	702	-	-	HYPH	B-NP
I-Cancer	702	706	cell	cell	NN	I-NP
I-Cancer	707	716	lymphomas	lymphoma	NNS	I-NP
O	716	717	,	,	,	O
O	718	720	18	18	CD	B-NP
B-Cancer	721	731	postthymic	postthymic	JJ	I-NP
I-Cancer	732	733	T	T	NN	I-NP
I-Cancer	733	734	-	-	HYPH	B-NP
I-Cancer	734	738	cell	cell	NN	I-NP
I-Cancer	739	748	lymphomas	lymphoma	NNS	I-NP
O	749	750	(	(	(	O
O	750	753	one	one	CD	B-NP
O	754	758	case	case	NN	I-NP
B-Cancer	759	762	CD8	CD8	NN	I-NP
I-Cancer	762	763	+	+	SYM	B-NP
I-Cancer	764	768	CD56	CD56	NN	I-NP
I-Cancer	768	769	+	+	SYM	B-NP
O	770	773	and	and	CC	O
O	774	779	three	three	CD	B-NP
B-Cancer	780	790	anaplastic	anaplastic	JJ	I-NP
I-Cancer	791	796	large	large	JJ	I-NP
I-Cancer	797	801	cell	cell	NN	I-NP
I-Cancer	802	811	lymphomas	lymphoma	NNS	I-NP
O	812	813	(	(	(	O
B-Cancer	813	817	ALCL	ALCL	NN	B-NP
O	817	818	)	)	)	O
O	818	819	,	,	,	O
O	820	825	three	three	CD	B-NP
B-Cancer	826	827	T	T	NN	I-NP
I-Cancer	827	828	-	-	HYPH	I-NP
I-Cancer	828	841	lymphoblastic	lymphoblastic	JJ	I-NP
I-Cancer	842	851	lymphomas	lymphoma	NNS	I-NP
O	851	852	,	,	,	O
O	853	856	and	and	CC	O
O	857	859	20	20	CD	B-NP
B-Cancer	860	861	B	B	NN	I-NP
I-Cancer	861	862	-	-	HYPH	B-NP
I-Cancer	862	866	cell	cell	NN	I-NP
I-Cancer	867	876	lymphomas	lymphoma	NNS	I-NP
O	876	877	.	.	.	O

O	878	886	Nineteen	Nineteen	CD	B-NP
O	887	888	(	(	(	O
O	888	890	79	79	CD	B-NP
O	890	891	%	%	NN	I-NP
O	891	892	)	)	)	O
O	893	901	putative	putative	JJ	B-NP
B-Cancer	902	904	NK	NK	NN	I-NP
I-Cancer	904	905	-	-	HYPH	B-NP
I-Cancer	905	909	cell	cell	NN	I-NP
I-Cancer	910	919	lymphomas	lymphoma	NNS	I-NP
O	920	929	expressed	express	VBD	B-VP
O	930	938	perforin	perforin	NN	B-NP
O	938	939	,	,	,	O
O	940	943	and	and	CC	O
O	944	947	all	all	DT	B-NP
O	948	950	24	24	CD	I-NP
O	951	956	cases	case	NNS	I-NP
O	957	966	expressed	express	VBD	B-VP
O	967	975	granzyme	granzyme	NN	B-NP
O	976	978	B9	B9	NN	I-NP
O	979	982	and	and	CC	I-NP
O	983	987	TIA1	TIA1	NN	I-NP
O	987	988	.	.	.	O

O	989	992	The	The	DT	B-NP
O	993	997	only	only	JJ	I-NP
B-Cancer	998	1001	CD8	CD8	NN	I-NP
I-Cancer	1001	1002	+	+	SYM	B-NP
I-Cancer	1003	1007	CD56	CD56	NN	I-NP
I-Cancer	1007	1008	+	+	SYM	B-NP
I-Cancer	1009	1019	postthymic	postthymic	JJ	I-NP
I-Cancer	1020	1021	T	T	NN	I-NP
I-Cancer	1021	1022	-	-	HYPH	I-NP
I-Cancer	1022	1026	cell	cell	NN	I-NP
I-Cancer	1027	1035	lymphoma	lymphoma	NN	I-NP
O	1036	1040	also	also	RB	B-ADVP
O	1041	1050	expressed	express	VBD	B-VP
O	1051	1054	all	all	DT	B-NP
O	1055	1060	three	three	CD	I-NP
O	1061	1070	cytolytic	cytolytic	JJ	I-NP
O	1071	1078	markers	marker	NNS	I-NP
O	1078	1079	,	,	,	O
O	1080	1083	two	two	CD	B-NP
B-Cancer	1084	1087	CD8	CD8	NN	I-NP
I-Cancer	1087	1088	-	-	HYPH	B-NP
I-Cancer	1089	1093	ALCL	ALCL	NN	I-NP
O	1094	1103	expressed	express	VBD	B-VP
O	1104	1108	TIA1	TIA1	NN	B-NP
O	1108	1109	;	;	:	O
O	1110	1115	other	other	JJ	B-NP
B-Cancer	1116	1126	postthymic	postthymic	JJ	I-NP
I-Cancer	1127	1128	T	T	NN	I-NP
I-Cancer	1128	1129	-	-	HYPH	B-NP
I-Cancer	1129	1133	cell	cell	NN	I-NP
O	1133	1134	,	,	,	O
B-Cancer	1135	1136	T	T	NN	B-NP
I-Cancer	1136	1137	-	-	HYPH	B-VP
I-Cancer	1137	1150	lymphoblastic	lymphoblastic	JJ	B-ADJP
O	1150	1151	,	,	,	O
O	1152	1155	and	and	CC	O
B-Cancer	1156	1157	B	B	NN	B-NP
I-Cancer	1157	1158	-	-	HYPH	B-NP
I-Cancer	1158	1162	cell	cell	NN	I-NP
I-Cancer	1163	1172	lymphomas	lymphoma	NNS	I-NP
O	1173	1177	were	be	VBD	B-VP
O	1178	1190	consistently	consistently	RB	B-ADJP
O	1191	1199	negative	negative	JJ	I-ADJP
O	1199	1200	.	.	.	O

O	1201	1206	There	There	EX	B-NP
O	1207	1210	was	be	VBD	B-VP
O	1211	1217	strong	strong	JJ	B-NP
O	1218	1229	correlation	correlation	NN	I-NP
O	1230	1237	between	between	IN	B-PP
O	1238	1248	percentage	percentage	NN	B-NP
O	1249	1257	perforin	perforin	NN	I-NP
O	1257	1258	-	-	HYPH	B-NP
O	1258	1266	positive	positive	JJ	I-NP
B-Cell	1267	1272	cells	cell	NNS	I-NP
O	1273	1276	and	and	CC	O
O	1277	1282	zonal	zonal	JJ	B-NP
B-Cell	1283	1288	tumor	tumor	NN	I-NP
I-Cell	1289	1293	cell	cell	NN	I-NP
O	1294	1299	death	death	NN	I-NP
O	1299	1300	.	.	.	O

O	1301	1314	Angioinvasion	Angioinvasion	NN	B-NP
O	1314	1315	,	,	,	O
O	1316	1318	in	in	IN	B-PP
O	1319	1327	contrast	contrast	NN	B-NP
O	1327	1328	,	,	,	O
O	1329	1332	was	be	VBD	B-VP
O	1333	1340	present	present	JJ	B-ADJP
O	1341	1345	only	only	RB	B-PP
O	1346	1348	in	in	IN	I-PP
O	1349	1350	a	a	DT	B-NP
O	1351	1361	proportion	proportion	NN	I-NP
O	1362	1363	(	(	(	O
O	1363	1365	37	37	CD	B-NP
O	1365	1366	%	%	NN	I-NP
O	1366	1367	)	)	)	O
O	1368	1370	of	of	IN	B-PP
O	1371	1376	these	these	DT	B-NP
B-Cancer	1377	1386	lymphomas	lymphoma	NNS	I-NP
O	1387	1394	despite	despite	IN	B-PP
O	1395	1398	the	the	DT	B-NP
O	1399	1407	frequent	frequent	JJ	I-NP
O	1408	1416	presence	presence	NN	I-NP
O	1417	1419	of	of	IN	B-PP
O	1420	1425	zonal	zonal	JJ	B-NP
B-Cell	1426	1431	tumor	tumor	NN	I-NP
I-Cell	1432	1436	cell	cell	NN	I-NP
O	1437	1442	death	death	NN	I-NP
O	1443	1444	(	(	(	O
O	1444	1446	71	71	CD	B-NP
O	1446	1447	%	%	NN	I-NP
O	1447	1448	)	)	)	O
O	1448	1449	.	.	.	O

O	1450	1452	We	We	PRP	B-NP
O	1453	1460	propose	propose	VBP	B-VP
O	1461	1465	that	that	IN	B-SBAR
O	1466	1475	cytolytic	cytolytic	JJ	B-NP
O	1476	1484	effector	effector	NN	I-NP
O	1485	1488	and	and	CC	O
O	1489	1496	related	related	JJ	B-NP
O	1497	1505	proteins	protein	NNS	I-NP
O	1506	1514	produced	produce	VBN	B-VP
O	1515	1517	by	by	IN	B-PP
O	1518	1526	putative	putative	JJ	B-NP
B-Cell	1527	1529	NK	NK	NN	I-NP
O	1530	1533	and	and	CC	O
O	1534	1538	some	some	DT	B-NP
B-Cancer	1539	1542	CD8	CD8	NN	I-NP
I-Cancer	1542	1543	+	+	SYM	B-NP
I-Cancer	1544	1548	CD56	CD56	NN	I-NP
I-Cancer	1548	1549	+	+	SYM	B-NP
I-Cancer	1550	1560	postthymic	postthymic	JJ	I-NP
I-Cancer	1561	1562	T	T	NN	I-NP
I-Cancer	1562	1563	-	-	HYPH	I-NP
I-Cancer	1563	1567	cell	cell	NN	I-NP
I-Cancer	1568	1577	lymphomas	lymphoma	NNS	I-NP
O	1577	1578	,	,	,	O
O	1579	1587	probably	probably	RB	B-ADVP
O	1588	1590	in	in	IN	B-PP
O	1591	1602	conjunction	conjunction	NN	B-NP
O	1603	1607	with	with	IN	B-PP
O	1608	1613	other	other	JJ	B-NP
O	1614	1624	mechanisms	mechanism	NNS	I-NP
O	1624	1625	,	,	,	O
O	1626	1629	may	may	MD	B-VP
O	1630	1636	effect	effect	VB	I-VP
O	1637	1644	massive	massive	JJ	B-NP
B-Cell	1645	1650	tumor	tumor	NN	I-NP
I-Cell	1651	1655	cell	cell	NN	I-NP
O	1656	1665	apoptosis	apoptosis	NN	I-NP
O	1665	1666	.	.	.	O

O	1667	1670	The	The	DT	B-NP
O	1671	1679	frequent	frequent	JJ	I-NP
O	1680	1690	expression	expression	NN	I-NP
O	1691	1693	of	of	IN	B-PP
O	1694	1703	cytolytic	cytolytic	JJ	B-NP
O	1704	1712	effector	effector	NN	I-NP
O	1713	1720	markers	marker	NNS	I-NP
O	1721	1723	in	in	IN	B-PP
O	1724	1727	the	the	DT	B-NP
B-Cancer	1728	1731	CD2	CD2	NN	I-NP
I-Cancer	1731	1732	+	+	CC	I-NP
I-Cancer	1733	1740	surface	surface	NN	I-NP
I-Cancer	1741	1744	CD3	CD3	NN	I-NP
I-Cancer	1744	1745	-	-	HYPH	B-NP
I-Cancer	1746	1750	CD56	CD56	NN	I-NP
I-Cancer	1750	1751	+	+	SYM	B-NP
I-Cancer	1752	1760	putative	putative	JJ	B-NP
I-Cancer	1761	1763	NK	NK	NN	I-NP
I-Cancer	1763	1764	-	-	HYPH	B-NP
I-Cancer	1764	1768	cell	cell	NN	I-NP
I-Cancer	1769	1778	lymphomas	lymphoma	NNS	I-NP
O	1779	1784	lends	lend	VBZ	B-VP
O	1785	1792	further	further	JJ	B-NP
O	1793	1800	support	support	NN	I-NP
O	1801	1803	to	to	TO	B-PP
O	1804	1809	their	their	PRP$	B-NP
O	1810	1818	probable	probable	JJ	I-NP
B-Cell	1819	1821	NK	NK	NN	I-NP
I-Cell	1822	1826	cell	cell	NN	I-NP
O	1827	1833	origin	origin	NN	I-NP
O	1833	1834	.	.	.	O

